64
DYRK1A Protein inhibitor_ Down's syndrome, AD
CNRS
Small molecule
Neurology, CNS disease
Target Identification or Validation
The present invention discloses compositions of novel DYRK1A protein inhibitors based on a 3,5-diarylazaindole motif and their preparation and use as medications in the treatment of cognitive disorders associated with dysfunction of DYRK1A protein, with Down's syndrome and with Alzheimer's disease
PCT-EP2013-077224
